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Treatment decisions are difficult in clinically localised prostate cancer and further biomarkers of 
aggressive behaviour are required. We investigated the hypothesis that the tissue expression of three 
cell cycle markers, Rb, p21 and p16, would provide helpful prognostic information in a well 
characterised series of prostate cancers which were clinically localised and treated conservatively. 
The immunohistochemical staining expression of these markers was assessed in tissue microarrays 
and correlated with 10 year prostate cancer survival and overall survival and then compared with 
pathological data including contemporary Gleason score, measures of tumour extent and initial PSA 
level.  
Rb over-expression did not show any significant association with Gleason score or prostate cancer 
survival. P21 protein expression showed a significant association with Prostate cancer survival (p = 
0.02) and overall survival (p=0.01) in a univariate model but not in a multivariate model with 
pathological and Prostate Specific Antigen data  
There was a significant association between p16 cytoplasmic expression and Prostate cancer 
survival (HR=2.52, CI=1.79-3.55, p<0.001) and overall survival (HR=1.54, CI=1.20-1.98, p=0.001) 
in a univariate model. P16 expression remained an independent prognostic factor for Prostate cancer 
survival (HR=1.50, 95% CI=1.05-2.14, p=0.03). 
We conclude that p16 cytoplasmic expression is a strong predictor of outcome in conservatively 
treated prostate cancer. Rb and p21 show no independent association with outcome and therefore 
further research is not warranted. 
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Prostate cancer (PCa) is the second most common malignancy after lung cancer among men 
worldwide [1]. The incidence of PCa has increased over the past 20 years but this has not been 
reflected in the mortality rate. This is mainly due to an increase in Prostate specific antigen (PSA) 
screening despite its lack of specificity[2]. However, in many countries, prostate cancer is now 
diagnosed at a clinically localised asymptomatic stage. Curative treatment options for localised PCa 
include radical surgery, external beam radiotherapy, cryoablation and brachytherapy. While radical 
treatments are often curative, many tumours are indolent and would not have progressed within a 
patient’s lifetime. Gleason score and serum Prostate Specific Antigen (PSA) remain only moderate 
predictors for outcome and further biomarkers are required to refine risk of progression. 
The Transatlantic Prostate Group (TAPG) was created to collect and study a large retrospective 
cohort of clinically localised patients with contemporary Gleason score and serum PSA [3]. Tissue 
collected from this study is available as a resource to identify potential biomarkers that can predict 
PCa progression for eventual adoption into clinical use. As nearly all biomarker studies on prostate 
cancer examine tumours treated by radical means, the TAPG study enables an insight into the 
‘natural history’ of the disease,. These cell cycle proteins were chosen as they represent part of a 
well known pathway, widely studied in prostate cancer, and that they all have potential to be 
translated to clinical use, as they are used in routine on a regular basis. 
Rb is a tumour suppressor gene which regulates transition between G1 and S phases of the cell 
cycle. Loss of heterozygosity of Rb in PCa has demonstrated by several studies [4] [5] [6]. P21 acts 
as a tumour suppressor protein and initiates cell cycle arrest by inhibiting the activity of Cyclin 
dependent kinases (Cdk) 2, 3, 4 and 6 which have a direct role in the G1-S transition. In a quiescent 
cell p21 expression is low but it increases in response to mitogenic signals during the G1 phase 
progression. P21 is activated via p53 independent as well as dependent pathways. Gao et al., (1995) 
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identified a mutation of the p21 gene in PCa but in majority of PCa, p21 seem to be over-expressed 
rather than mutated [7].  
P16 is also a tumour suppressor protein which is linked to Rb pathway and is located on 
chromosome 9p21-22.  P16 belongs to the INK4a family where the p16 regulatory protein binds to 
cyclin dependent kinase 4 or 6 and inhibit cyclin D-dependent kinase phosphorylation of Rb.  This 
halts the progression of G1 to S phase leaving the cells to repair or senesce. Loss of function of p16 
due to mutation, deletion and loss of heterozygosity is common in human tumours. Over-expression 
of p16 correlates with tumour recurrence in radical prostatectomy patients [8].  
Most of the studies related to the above mentioned proteins and PCa are on radical prostatectomy 
cohorts, radiotherapy groups or hormonal therapy groups. The relationship between each of the 
protein expressions above and their prognostic value on PCa have not been investigated in a 
conservatively treated cohort. In this study the TAPG cohort was utilised to test the hypothesis that 
this protein expression information might add to the overall prognostic model and assist in patient 
risk assessment. 
Material and methods 
Detailed information on patient data collection was published previously [3]. In brief, the patient 
information and tissues were collected from six cancer registries in the UK. Patients were diagnosed 
with clinically localised PCa by trans-urethral resection of prostate (TURP) or needle biopsies 
between the years 1990 and 1996. The patients were included only if PSA level was available pre-
diagnosis and less than 100ng/ml and were under the age of 76 years.The diagnosis and Gleason 
score was re-assessed by an expert GU pathologist. Patients were excluded if they had radical 
surgery or radiotherapy within 6 months of diagnosis or if there was objective evidence of 
metastasis or clinical indication of metastasis. There were 1656 patients in total. After 10 years 
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follow up a prognostic model including Gleason score, clinical stage, age, extent of disease and 
PSA level was created.  
Tissue from the TURPs, which was 55% of the cohort, was tissue microarrayed (TMA) into 24 wax 
blocks. Multiple (usually 3) tissue cores with a 0.6mm diameter were taken from each formalin 
fixed donor block and was transferred into a new recipient wax block. Four µm thick sections were 
cut from the TMA blocks and were immunohistochemically (IHC) stained for Rb, p21 and p16 
using the following clones: Retinoblastoma, (Novocastra, Newcastle Upon Tyne, U.K) at a dilution 
of 1/50, p21 (DakoCytomation, Cambridgeshire, U.K) at a dilution of 1/1000, and p16 (Neomarkers, 
California, U.S.A) at a dilution of 1/100. Antigen retrieval by pressure cooking in citrate buffer at 
pH=6.0 was performed for Rb and p21. Diaminobenzidine was used as a chromogen and the slides 
were counterstained by hematoxylin. Hyperplastic tonsil, normal placenta, and cervical 
intraepithelial neoplasia grade 3 were used as positive controls for Rb, p21, and p16 respectively. 
The TMA without primary antibody incubation was used as negative control.  
The protein expression was analysed semi-quantitatively. The percentage expression (P) was 
assessed between 0-100% and the intensity of the staining (I) was assessed between 0= no staining, 
1=weak, 2=medium and 3=strong. This allowed an immunostaining score (IS) between 0-300, 
where IS= I x P. For p21 and Rb, only nuclear staining was assessed. For P16 expression both 
nuclear and cytoplasmic expressions were scored. 
The maximum stained core was considered as representation of tumour progression for p21 and p16 
and the minimum stained core was considered for Rb as loss of immunoexpression was taken as a 
reflection of tumour progression. For each protein, the correlation of IS with demographics and 
tumour characteristics, including Gleason score, was examined (using the w2 test and Fisher’s exact 
test for categorical variables and analysis of variance for numerical variables). The main end points 
were time to death from PCa and time to death from any cause. Univariate and multivariate 
analyses were performed by proportional hazard (Cox) regression analysis. The multivariate models 
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include Gleason score, age at diagnosis, baseline PSA level and extent of disease. All p values were 
two sided and 95% confidence intervals (CIs) were based on normal distribution.  
Results 
Rb 
1809 tissue cores were identified as cancer representing 702 patients with Rb expression data.  The 
Rb protein expression was compared with Gleason score, clinical stage and initial PSA value. There 
was no significant association between Rb protein expression and Gleason score (p=0.78). There 
was no association between Rb expression and PCa survival (HR=0.98, 95% CI=0.67-1.45, p=0.94) 
nor with overall survival (HR=0.88, 95% CI=0.68-1.14, p=0.34) in univariate analyses. In a 
multivariate model including Gleason score, age and extent of disease Rb expression did not show 
any significant association between PCa survival (HR=1.16, 95% CI=0.78-1.72, p=0.46) and 
overall survival (HR=0.98, 95% CI=0.76-1.27, p=0.88).  
P21 
Expression of p21 protein was analysed in 1789 cancer tissue cores which represented 694 patients. 
The p21 expression was significantly correlated with Gleason score (p < 0.001). Both PCa survival 
(HR=1.61, 95% CI=1.08-2.42, p=0.02) (Figure1) and overall survival (HR=1.42, 95% CI=1.08-
1.86, p=0.01) showed significant correlation with p21 protein expression in a univariate model but 
failed to show any significance in a multivariate model.  
P16 
There was information of nuclear expression and cytoplasmic expression for 1287 cancer cores 
which was a representative of 534 patients. Both p16 nuclear expression (p=0.001) and cytoplasmic 
expression (p<0.001) were significantly associated with Gleason score. There was a significant 
association between PCa survival (HR=2.52, CI=1.79-3.55, p<0.001) and overall survival 
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(HR=1.54, CI=1.20-1.98, p=0.001) in a univariate model for p16 cytoplasmic expression. In a 
multivariate setting including Gleason score, age, extent of disease and PSA level, p16 cytoplasmic 
expression  remained a independent prognostic factor for PCa survival (HR=1.50, 95% CI=1.05-
2.14, p=0.03) (Figure2). P16 nuclear expression was significantly associated with PCa survival 
(HR=1.63, CI= 1.13-2.34, p=0.008) but not with overall survival in a univariate model and did not 
remain significant in a multivariate model.  
Discussion 
The immense size of the literature on biomarkers in prostate cancer has not translated into the use of 
any candidate tissue markers into current clinical practice. This is for many reasons, but the most 
important is that most biomarker assessments occur on radical prostatectomy specimens, or on 
biopsies of patients who undergo some other form of radical treatment such as radiotherapy. 
However, decisions on definitive treatment are made after diagnosis, but prior to treatment, either 
on TURP, or more usually in trans-rectal ultrasound biopsy specimens. The TAPG series is the only 
conservatively treated cohort with extended follow up, contemporary Gleason scoring and serum 
PSA in which translational material is available. It is therefore a tool to consider those biomarkers 
which may be of use in future or current prospective series which may yield translational tissue 
resources. Comparing this study with other comparable series with long term follow up, the study 
by Albertsen et al, has not yielded translational data while the study by Mucci et al  on the cohort 
developed by Johannson et al has not yet yielded significant information [9], [10], [11]. Unfortunately, 
this latter series does not include pre-diagnostic serum PSA measurements. There is no current 
cohort of patients treated in a uniform fashion by either active surveillance or watchful waiting in 
which translational material is yet available. Although ideally, such a series would be conducted on 
biopsy material, conforming to modern methods of diagnosis, we here utilised TURP tissue which 
constituted 55% of our series. Our future aim is to translate promising biomarkers in the TURP 
material into the much more difficult biopsy series where tissue is extremely limited. It should be 
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noted that for our multivariate analyses we included  disease extent as well as Gleason score and 
serum PSA level to ensure that as much prognostic information as possible could be extracted from 
standard parameters. 
These data show that Rb is not a promising biomarker for disease outcome.  Deletion of the Rb 
gene and loss of expression has been long reported in PCa [12]. Rb protein in tumour tissue can 
either be down-regulated due to loss of function or due to interactions of redundantly acting genes 
which mask the expression of Rb protein [13]. Previous studies of Rb protein expression 
unfortunately did not show significant associations with the clinical and pathological parameters but 
one paper did show a significant association with disease specific survival [14]. Our study showed 
reduced Rb expression with most of the cancer tissue showing weak staining intensity. This has 
been observed in quite a few studies [15], [16], [17] done on early stage PCa. If the Rb gene is mutated 
the tumour suppressor function will be altered and this may be another reason for reduced Rb 
protein expression. The anti Rb antibody that was used in the study only recognised the 
unphosphorylated Rb, which should have identified all the unphosphorylated Rb in the nucleus and 
if Rb has lost its function due to one inactive gene the other half of the gene which is active has the 
ability to express Rb.  
P21 protein expression showed a significant association with Gleason score in addition to PCa 
survival and overall survival in a univariate model. Association between p21 protein expression 
with survival varies between cancer types. In colorectal cancer [18], bladder cancer [19] and 
hepatocellular carcinoma [20] reduced or absence of p21 expression was correlated with poor 
clinical outcome, but in breast cancer [21], carcinoma of the head and neck [22] and esophageal 
carcinoma [23] p21 over-expression was associated with worse prognosis. Nevertheless expression 
of p21 protein was shown to be correlated with the Gleason score in two previous studies on 
radically treated cancers [24], [25]. Although the results were significant in a univariate model, the 
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lack of significance in a multivariate model, suggest that this marker is not sufficiently powerful to 
progress to the future experimental stage of testing in a biopsy cohort. 
The cytoplasmic expression of P16 was significantly correlated to PCa survival in both univariate 
and multivariate models. Jarrard et al (2002) showed an association with p16 protein expression and 
Gleason score as an independent variable, also Henshall et al, in a multivariate model showed 
association with both Gleason score and clinical stage [26], [27] in radically treated disease. 
Development of a standardised IHC technique for p16 expression cut-off may increase the 
acceptability as a prognostic method so that it can be used in a clinical setting. A major 
disadvantage of IHC is that there is an absence of standardised techniques, either nationally or 
internationally. This reduces its acceptability as a robust technique for clinical diagnosis. It is 
possible, in common with a number of other studies, that cytoplasmic expression of p16 is 
representative of aberrant expression secondary to mutation, deletion or loss of heterozygosity.  
In this unique series of conservatively treated prostate cancers p16 cytoplasmic expression proved 
an independent predictor of prostate cancer death, whereas Rb and p21 did not add to this 
prognostic model. We suggest that p16 but not Rb or p21 be investigated further for potential 
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